MedPath

Tamoxifen

Generic Name
Tamoxifen
Brand Names
Soltamox
Drug Type
Small Molecule
Chemical Formula
C26H29NO
CAS Number
10540-29-1
Unique Ingredient Identifier
094ZI81Y45
Background

Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with anastrozole.

Tamoxifen was granted FDA approval on 30 December 1977.

Indication

Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.

Associated Conditions
Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
Associated Therapies
Ovulation induction therapy
Clinical Trials
Related News

Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: Anastrozole
Drug: Tamoxifen
First Posted Date
2006-02-07
Last Posted Date
2009-06-09
Lead Sponsor
AstraZeneca
Target Recruit Count
1059
Registration Number
NCT00287534
Locations
🇩🇪

Research Site, Wuerzburg, Germany

ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years

Phase 3
Completed
Conditions
Breast Cancer
Interventions
Drug: Anastrozole
Drug: Tamoxifen
First Posted Date
2006-02-03
Last Posted Date
2009-05-01
Lead Sponsor
AstraZeneca
Target Recruit Count
448
Registration Number
NCT00286117
Locations
🇮🇹

Research Site, Vicenza, Italy

Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer

Phase 3
Completed
Conditions
Breast Neoplasms
Interventions
Drug: exemestane
Drug: tamoxifen
First Posted Date
2006-01-19
Last Posted Date
2011-12-23
Lead Sponsor
Pfizer
Target Recruit Count
9779
Registration Number
NCT00279448
Locations
🇫🇷

Pfizer Investigational Site, Vannes, France

A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer

Phase 3
Completed
Conditions
Breast Cancer
Metastasis
Interventions
Drug: Tamoxifen
Drug: Fulvestrant
First Posted Date
2005-10-19
Last Posted Date
2012-06-06
Lead Sponsor
AstraZeneca
Target Recruit Count
51
Registration Number
NCT00241449
Locations
🇬🇧

Research Site, York, United Kingdom

Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer

Phase 3
Completed
Conditions
Prostate Cancer
First Posted Date
2005-10-06
Last Posted Date
2011-01-27
Lead Sponsor
AstraZeneca
Target Recruit Count
180
Registration Number
NCT00233610
Locations
🇮🇹

Research Site, Roma, Italy

Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

Phase 2
Completed
Conditions
Breast Neoplasms
Interventions
Drug: Gefitinib
Drug: Tamoxifen
First Posted Date
2005-09-30
Last Posted Date
2015-10-05
Lead Sponsor
AstraZeneca
Target Recruit Count
317
Registration Number
NCT00229697
Locations
🇬🇧

Research Site, Nottingham, United Kingdom

Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer

Phase 2
Terminated
Conditions
Breast Neoplasms
First Posted Date
2005-09-21
Last Posted Date
2006-11-14
Lead Sponsor
Institut Claudius Regaud
Target Recruit Count
40
Registration Number
NCT00210028
Locations
🇫🇷

Institut Bergonie, Bordeaux, France

🇫🇷

Institut Val d'Aurelle_ Paul Lamarque, Montpellier, France

🇫🇷

Institut Claudius Regaud, Toulouse, France

Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]

Phase 2
Completed
Conditions
Amyotrophic Lateral Sclerosis (ALS)
First Posted Date
2005-09-21
Last Posted Date
2015-10-05
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
100
Registration Number
NCT00214110
Locations
🇺🇸

University of Wisconsin, Madison, Wisconsin, United States

Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients

Phase 2
Terminated
Conditions
Breast Cancer
Interventions
Drug: Iressa
Drug: Tamoxifen
First Posted Date
2005-09-21
Last Posted Date
2017-08-01
Lead Sponsor
Baylor Breast Care Center
Target Recruit Count
3
Registration Number
NCT00206492
Locations
🇺🇸

Baylor Breast Center, Houston, Texas, United States

Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women?

Phase 2
Completed
Conditions
Bipolar Disorder
Mania
Schizoaffective Disorder
Interventions
Other: placebo
Drug: Tamoxifen
Drug: Progesterone
First Posted Date
2005-09-21
Last Posted Date
2008-10-24
Lead Sponsor
The Alfred
Target Recruit Count
51
Registration Number
NCT00206544
Locations
🇦🇺

Bayside Health - The Alfred Hospital, Melbourne, Victoria, Australia

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy